Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. (Q44016847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

D M Flavell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

E Hawe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

P K MacCallum

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

T W Meade

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

S E Humphries

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

163

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

183-192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

Femoral atherosclerosis in an older British population: prevalence and risk factors

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Lower extremity arterial disease and the aging process: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol--the Reykjavik Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Prevalence of intermittent claudication and its effect on mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Intermittent claudication: prevalence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrinogen as a risk factor for stroke and myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Intermittent claudication in 8343 men and 21-year specific mortality follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Intermittent claudication and subsequent cardiovascular disease in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Mortality over a period of 10 years in patients with peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Regulation of apo A-I gene expression by fibrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

A simple salting out procedure for extracting DNA from human nucleated cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Association of genetic variation at the beta-fibrinogen gene locus and plasma fibrinogen levels; interaction between allele frequency of the G/A-455 polymorphism, age and smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Differential activation of peroxisome proliferator-activated receptors by eicosanoids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2802%2900002-3

10.1016/S0021-9150(02)00002-3

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048138%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference